In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.
The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.
Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.
The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.
In 1933 the Austrian psychiatrist Manfred Sakel announced from Vienna that he could break schizophrenia by injecting patients with enough insulin to crash their blood sugar into deep coma — and reported, on uncontrolled case series with no comparison group, recovery rates of 70 to 80 percent; the distance between that claim and what a controlled trial eventually found is the whole of this case. The procedure that resulted held patients in repeated, deliberately induced hypoglycemic comas — typically a course of 20 to 60 sessions, each lasting up to an hour, terminated by glucose — across asylums in Europe and North America for two decades, and killed on the order of one to two patients in every hundred treated, with some series running higher.
Insulin coma therapy (ICT) did not survive on evidence. It survived on enthusiasm and on a flattering selection effect. As the British psychiatrist Harold Bourne argued in his 1953 Lancet paper “The Insulin Myth,” ICT units selected younger, recently-ill, better-prognosis patients, lavished them with intensive nursing in dedicated wards, and then credited insulin for an improvement that the selection and the attention had largely produced. Bourne’s verdict — that insulin patients were “an elite group sharing common privileges and perils,” and that the coma added nothing specific — was a theoretical demolition that the field initially refused to print; the Journal of Mental Science sat on his manuscript for a year and rejected it, telling him to “get more experience.”
The empirical reckoning arrived in 1957, when Brian Ackner, Arthur Harris and A.J. Oldham published in The Lancet one of the first randomized controlled trials in psychiatric history. Fifty schizophrenia patients were randomly allocated either to insulin coma or to an identical regimen in which the unconsciousness was produced by barbiturates instead — same ward, same nursing, same coma, different agent. There was no difference in outcome. Whatever the regimen achieved, insulin was not the active ingredient. Within a few years ICT had collapsed, helped over the edge by chlorpromazine, which by the late 1950s delivered comparable results without driving anyone into a coma. It was never recalled and never banned; it was simply discredited and abandoned, and it is now taught as the first major therapy retired by a randomized controlled trial — and a textbook illustration of how a selection effect can masquerade as a cure.
For roughly the first three-quarters of the twentieth century, tonsillectomy was the most frequently performed operation in the United States — a near-compulsory rite of childhood scheduled on the order of a million-plus times a year for sore throats, “mouth breathing,” poor appetite, and the vague proposition that a child would simply be healthier without tonsils; the gap between that universal promise and the evidence is the entire case, because the operation was never shown to deliver the broad benefits claimed, killed a measurable number of the children it was sold to protect, and for a period in the 1940s demonstrably raised the risk of paralytic polio. At its 1959 peak roughly 1.4 million tonsillectomies were performed annually in the U.S., the overwhelming majority on children, and by mid-century an estimated 30 percent of American children had lost their tonsils — many to surgeons who, examined honestly, could not say why.
The procedure rode the “focal infection” theory: the early-twentieth-century belief that lurking pockets of chronic infection in the tonsils seeded disease throughout the body and were best excised pre-emptively. On that theory the indication became, in practice, the mere possession of tonsils. The surrogate that justified the knife was not a measured health outcome but a clinical impression — the tonsils “looked enlarged” — and impressions, it turned out, were nearly random. In 1934 the American Child Health Association sent 1,000 New York schoolchildren through successive examinations and found 61 percent had already been tonsillectomized; of the remaining 39 percent, physicians recommended surgery for all but 65, then for nearly half of those who had just been cleared, and again for nearly half of that residue — a recursive demonstration that the indication lived in the examiner, not the child.
The disconfirming evidence accumulated for forty years before the practice yielded. James Alison Glover’s 1938 study showed English tonsillectomy rates varying by an order of magnitude between districts with no relation to disease — the founding observation of “unwarranted variation,” still called the Glover phenomenon. From 1942 onward, epidemiologists documented that children tonsillectomized shortly before exposure to poliovirus suffered the deadly bulbar form at multiples of the background rate. And in 1984 the first rigorous randomized trial, by Jack Paradise in the New England Journal of Medicine, found a real but narrow benefit only for the most severely and frequently infected children — a tiny slice of those who had been operated on for decades. The operation was not banned. It was restricted, its indications tightened, its volume cut by more than half, retired from routine use by evidence that arrived long after the harm.